# Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment

> **NCT00445302** · PHASE1 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 23 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** plerixafor

## Key facts

- **NCT ID:** NCT00445302
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2014-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00445302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00445302, "Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00445302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*